Familial chylomicronemia syndrome (FCS) is one of the rarest and most challenging lipid disorders to manage, but the landscape is changing rapidly. In this Industry Innovations episode, guest host Kevin Maki, PhD, CLS, MNLA sits down with Archna Bajaj, MD, FNLA for a comprehensive and forward-looking conversation on FCS from every angle.
Dr. Bajaj walks through the realities of living with FCS — from diagnosis to the demands of a strict ultra-low-fat diet — before turning to what has the field buzzing: two landmark APOC3-targeting therapies and the clinical trial data behind them. A must-listen for any clinician caring for patients with rare lipid disorders, and a glimpse at a future where FCS management looks fundamentally different.
This episode’s topic comes courtesy of Arrowhead Pharmaceuticals, Inc. a member of the NLA Industry Council.
